Tinea Cruris

13 registered clinical trials studyying Tinea Cruris — 1 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	A Pilot Study to Evaluate the Therapeutic Efficacy of Intra-Lesional Immunotherapy in Patients Aged 10-60 Year NCT07312604	Abeer Mohamed Abdelaziz Elkholy	N/A
Completed	Comparative Efficacy of Topical Oxiconazole Cream (1%) Versus Topical Clotrimazole Cream (1%) in the Treatment NCT07441005	Hayat Abad Medical Complex, Peshawar	EARLY_Phase 1
Unknown	Efficacy and Safety of Terbinafine and Itraconazole NCT05881980	Dhaka Medical College	Phase 2 / Phase 3
Completed	Safety, Tolerability, and Pharmacokinetics of UHE-103 Cream in Subjects With Tinea Cruris and/or Tinea Pedis NCT05363449	Therapeutics, Inc.	Phase 1
Completed	Maximal Use of Luliconazole Cream 1% in Pediatric Participants With Moderate to Severe Tinea Pedis or Tinea Cr NCT02767271	Bausch Health Americas, Inc.	Phase 4
Completed	Study Evaluating the Drug Interaction Potential of Luliconazole Cream 1% in Participants With Tinea Pedis and NCT02394340	Bausch & Lomb Incorporated	Phase 4
Completed	Clinical Trial Comparing Dapaconazole Versus Miconazole in Patients With Tinea Cruris NCT03359070	Galeno Desenvolvimento de Pesquisas Clínicas	Phase 2
Completed	Evaluation of Efficacy and Safety of Naftin 1% Cream in Adolescent Subjects With Tinea Cruris NCT01885156	Merz North America, Inc.	Phase 3
Completed	Pharmacokinetic Study of Pediatric Subjects With Tinea Cruris and Tinea Pedis NCT01712360	Merz North America, Inc.	Phase 4
Unknown	Evaluate the Efficacy and Safety of Tolnaftate Cream in the Treatment of Patients With Fungal Infections NCT01105013	Laboratório Teuto Brasileiro S/A	Phase 3
Completed	Topical Antifungal Treatment for Tinea Cruris NCT01342315	Medicis Global Service Corporation	Phase 3
Completed	Safety of a Topical Antifungal Treatment for Tinea Cruris, Tinea Pedis and Tinea Corporis NCT01349998	Tinea Pharmaceuticals	Phase 3
Completed	Multicenter Study of the Safety and Efficacy of NAFT-500 in Tinea Cruris NCT00750152	Merz North America, Inc.	Phase 3